About GSK

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

£30.8bn
turnover in 2018
3
global businesses
300
years of innovation

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our 3 global businesses, scientific and technical know-how and talented people.

Pharmaceuticals
Vaccines
Consumer Healthcare

Pharmaceuticals

Immune system T-cells attacking a cancer cell

£17.3bn, +2% CER sales turnover 2018

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, use of genetics and advanced technologies.

Key products
Trelegy – Asthma/COPD
Nucala – Severe Asthma
Triumeq/Tivicay – HIV

Vaccines

£5.9bn, +16% CER sales turnover 2018

Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. We deliver over two million vaccine doses per day to people living in over 160 countries.

Key products
Shingrix – Shingles
Infanrix – Paediatric
Bexsero – Meningitis

Consumer Healthcare

Novamin, a key technology in Sensodyne Repair and Protect

£7.7bn, +2% CER sales turnover 2018

Our Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert recommended brands in the Pain relief, Respiratory, Digestive health, Oral health, Nutrition and Skin health categories.

On 19 December 2018 we announced our agreement with Pfizer to form a new world-leading Consumer Healthcare Joint Venture. Within 3 years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more

Key products
Sensodyne – Oral health
Voltaren – Pain relief (topical)
Panadol – Pain relief (systemic)

How we do it

Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust

Innovation
Performance
Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£3.9bn
R&D investment in 2018
33
of the 46 new medicines now in development targeting modulation of the immune system
17
immuno-oncology assets now in clinical development

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

£30.8bn
total turnover in 2018
£8.7bn
adjusted operating profit in 2018
£5.7bn
free cash flow in 2018
£3.9bn
dividends paid in 2018

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.